Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) Assets (2023 - 2025)

Tonix Pharmaceuticals Holding has reported Assets over the past 3 years, most recently at $277.2 million for Q4 2025.

  • Quarterly results put Assets at $277.2 million for Q4 2025, up 70.16% from a year ago — trailing twelve months through Dec 2025 was $277.2 million (up 70.16% YoY), and the annual figure for FY2025 was $277.2 million, up 70.16%.
  • Assets for Q4 2025 was $277.2 million at Tonix Pharmaceuticals Holding, up from $252.4 million in the prior quarter.
  • Over the last five years, Assets for TNXP hit a ceiling of $277.2 million in Q4 2025 and a floor of $70.3 million in Q2 2024.
  • Median Assets over the past 3 years was $161.3 million (2023), compared with a mean of $167.2 million.
  • Biggest five-year swings in Assets: plummeted 55.99% in 2024 and later skyrocketed 166.49% in 2025.
  • Tonix Pharmaceuticals Holding's Assets stood at $154.5 million in 2023, then rose by 5.46% to $162.9 million in 2024, then surged by 70.16% to $277.2 million in 2025.
  • The last three reported values for Assets were $277.2 million (Q4 2025), $252.4 million (Q3 2025), and $187.4 million (Q2 2025) per Business Quant data.